The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Tenofovir Nephrotoxicity: 2011 Update
Open accessAbstract
Tenofovir is an acyclic nucleotide analogue reverse-transcriptase inhibitor structurally similar to the nephrotoxic drugs adefovir and cidofovir. Tenofovir is widely used to treat HIV infection and approved for treatment of hepatitis B virus. Despite initial cell culture and clinical trials results supporting the renal safety of tenofovir, its clinical use is associated with a low, albeit significant, risk of kidney injury. Proximal tubular cell secretion of tenofovir explains the accumulation of the drug in these mitochondria-rich cells. Tenofovir nephrotoxicity is characterized by proximal tubular cell dysfunction that may be associated with acute kidney injury or chronic kidney disease. Withdrawal of the drug leads to improvement of analytical parameters that may be partial. Understanding the risk factors for nephrotoxicity and regular monitoring of proximal tubular dysfunction and serum creatinine in high-risk patients is required to minimize nephrotoxicity. Newer, structurally similar molecular derivatives that do not accumulate in proximal tubules are under study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization
Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E., & Hsu, C.-Y. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041031 · Cited by 11,369
Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury
Mehta, R. L., Kellum, J. A., Shah, S. V., Molitoris, B. A., Ronco, C., Warnock, D. G., Levin, A., & the Acute Kidney Injury Network (2007) · Critical Care · doi:10.1186/cc5713 · Cited by 7,048
Mitochondrial DNA mutations, oxidative stress, and apoptosis in mammalian aging
Kujoth, G. C., Hiona, A., Pugh, T. D., Someya, S., Panzer, K., Wohlgemuth, S. E., Hofer, T., Seo, A. Y., Sullivan, R., Jobling, W. A., et al. (2005) · Science · doi:10.1126/science.1112125 · Cited by 2,165
Gallant, J. E. (2004) · JAMA · doi:10.1001/jama.292.2.191 · Cited by 1,341
Kakuda, T. N. (2000) · Clinical Therapeutics · doi:10.1016/s0149-2918(00)90004-3 · Cited by 612
Gupta, S. K., Eustace, J. A., Winston, J. A., Boydstun, I. I., Ahuja, T. S., Rodriguez, R. A., Tashima, K. T., Roland, M., Franceschini, N., Palella, F. J., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/430257 · Cited by 581
Cooper, R. D., Wiebe, N., Smith, N., Keiser, P., Naicker, S., & Tonelli, M. (2010) · Clinical Infectious Diseases · doi:10.1086/655681 · Cited by 565
Mitochondrial toxicity of nrti antiviral drugs: an integrated cellular perspective
Lewis, W., Day, B. J., & Copeland, W. C. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1201 · Cited by 498
Bhaskaran, K. (2008) · JAMA · doi:10.1001/jama.300.1.51 · Cited by 496
Birkus, G., Hitchcock, M. J. M., & Cihlar, T. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.3.716-723.2002 · Cited by 441
Lalezari, J. P., Stagg, R. J., Kuppermann, B. D., Holland, G. N., Kramer, F., Ives, D. V., Youle, M., Robinson, M. R., Drew, W. L., & Jaffe, H. S. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-126-4-199702150-00001 · Cited by 372
Karras, A., Lafaurie, M., Furco, A., Bourgarit, A., Droz, D., Sereni, D., Legendre, C., Martinez, F., & Molina, J. (2003) · Clinical Infectious Diseases · doi:10.1086/368314 · Cited by 361
Nelson, M. R., Katlama, C., Montaner, J. S., Cooper, D. A., Gazzard, B., Clotet, B., Lazzarin, A., Schewe, K., Lange, J., Wyatt, C., et al. (2007) · AIDS · doi:10.1097/qad.0b013e3280b07b33 · Cited by 352
Herlitz, L. C., Mohan, S., Stokes, M. B., Radhakrishnan, J., D'Agati, V. D., & Markowitz, G. S. (2010) · Kidney International · doi:10.1038/ki.2010.318 · Cited by 348
Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis
Martin, J. L., Brown, C. E., Matthews-Davis, N., & Reardon, J. E. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.12.2743 · Cited by 343
Barditch-Crovo, P., Deeks, S. G., Collier, A., Safrin, S., Coakley, D. F., Miller, M., Kearney, B. P., Coleman, R. L., Lamy, P. D., Kahn, J. O., et al. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.10.2733-2739.2001 · Cited by 330
Mechanism of Active Renal Tubular Efflux of Tenofovir
Ray, A. S., Cihlar, T., Robinson, K. L., Tong, L., Vela, J. E., Fuller, M. D., Wieman, L. M., Eisenberg, E. J., & Rhodes, G. R. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00251-06 · Cited by 323
Tenofovir-Associated Acute and Chronic Kidney Disease: A Case of Multiple Drug Interactions
Zimmermann, A. E., Pizzoferrato, T., Bedford, J., Morris, A., Hoffman, R., & Braden, G. (2006) · Clinical Infectious Diseases · doi:10.1086/499048 · Cited by 314
Gallant, J. E., Parish, M. A., Keruly, J. C., & Moore, R. D. (2005) · Clinical Infectious Diseases · doi:10.1086/428840 · Cited by 302
Goicoechea, M., Liu, S., Best, B., Sun, S., Jain, S., Kemper, C., Witt, M., Diamond, C., Haubrich, R., Louie, S., et al. (2008) · The Journal of Infectious Diseases · doi:10.1086/524061 · Cited by 299
Labarga, P., Barreiro, P., Martin-Carbonero, L., Rodriguez-Novoa, S., Solera, C., Medrano, J., Rivas, P., Albalater, M., Blanco, F., Moreno, V., et al. (2009) · AIDS · doi:10.1097/qad.0b013e3283262a64 · Cited by 294
Schooley, R. T., Ruane, P., Myers, R. A., Beall, G., Lampiris, H., Berger, D., Chen, S.-S., Miller, M. D., Isaacson, E., & Cheng, A. K. (2002) · AIDS · doi:10.1097/00002030-200206140-00008 · Cited by 270
Renal Tubular Dysfunction Associated With Tenofovir Therapy: Report of 7 Cases
Peyri??re, H., Reynes, J., Rouanet, I., Daniel, N., de Boever, C. M., Mauboussin, J.-M., Leray, H., Moachon, L., Vincent, D., & Salmon-C??ron, D. (2004) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200403010-00007 · Cited by 262
Mechanisms of Renal Apoptosis in Health and Disease
Sanz, A. B., Santamari[Combining Acute Accent]a, B., Ruiz-Ortega, M., Egido, J., & Ortiz, A. (2008) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007121336 · Cited by 249
Self-citationHostetler, K. Y. (2009) · Antiviral Research · doi:10.1016/j.antiviral.2009.01.005 · Cited by 244
Cihlar, T., Ho, E. S., Lin, D. C., & Mulato, A. S. (2001) · Nucleosides, Nucleotides and Nucleic Acids · doi:10.1081/ncn-100002341 · Cited by 241
Rodríguez‐Nóvoa, S., Labarga, P., Soriano, V., Egan, D., Albalater, M., Morello, J., Cuenca, L., González‐Pardo, G., Khoo, S., Back, D., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/598507 · Cited by 241
Arribas, J. R., Pozniak, A. L., Gallant, J. E., DeJesus, E., Gazzard, B., Campo, R. E., Chen, S.-S., McColl, D., Holmes, C. B., Enejosa, J., et al. (2008) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31815acab8 · Cited by 235
Pozniak, A. L., Gallant, J. E., DeJesus, E., Arribas, J. R., Gazzard, B., Campo, R. E., Chen, S.-S., McColl, D., Enejosa, J., Toole, J. J., et al. (2006) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/01.qai.0000245886.51262.67 · Cited by 231
Lee, H., Hanes, J., & Johnson, K. A. (2003) · Biochemistry · doi:10.1021/bi035596s · Cited by 219
Adefovir nephrotoxicity: Possible role of mitochondrial DNA depletion
Tanji, N., Tanji, K., Kambham, N., Markowitz, G. S., Bell, A., & D'Agati, V. D. (2001) · Human Pathology · doi:10.1053/hupa.2001.25586 · Cited by 207
Tenofovir renal toxicity targets mitochondria of renal proximal tubules
Kohler, J. J., Hosseini, S. H., Hoying-Brandt, A., Green, E., Johnson, D. M., Russ, R., Tran, D., Raper, C. M., Santoianni, R., & Lewis, W. (2009) · Laboratory Investigation · doi:10.1038/labinvest.2009.14 · Cited by 195
Tenofovir-Associated Fanconi Syndrome: Review of the FDA Adverse Event Reporting System
Gupta, S. K. (2008) · AIDS Patient Care and STDs · doi:10.1089/apc.2007.0052 · Cited by 181
Renal safety of tenofovir in HIV treatment-experienced patients
Izzedine, H., Isnard-Bagnis, C., Hulot, J. S., Vittecoq, D., Cheng, A., Jais, C. K., Launay-Vacher, V., & Deray, G. (2004) · AIDS · doi:10.1097/00002030-200404300-00019 · Cited by 173
Gallant, J. E., & Deresinski, S. (2003) · Clinical Infectious Diseases · doi:10.1086/378068 · Cited by 162
Coca, S. G., & Perazella, M. A. (2002) · The American Journal of the Medical Sciences · doi:10.1097/00000441-200212000-00011 · Cited by 154
The nephrotoxic effects of HAART
Izzedine, H., Harris, M., & Perazella, M. A. (2009) · Nature Reviews Nephrology · doi:10.1038/nrneph.2009.142 · Cited by 144
Rompay, K. K. A. V., Brignolo, L. L., Meyer, D. J., Jerome, C. P., Tarara, R. P., Spinner, A., Hamilton, M., Hirst, L. L., Bennett, D. R., Canfield, D. R., et al. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.5.1469-1487.2004 · Cited by 140
Renal toxicity associated with tenofovir use
Rodríguez‐Nóvoa, S., Álvarez-Barco, E., Labarga, P., & Soriano, V. (2010) · Expert Opinion on Drug Safety · doi:10.1517/14740331003627458 · Cited by 131
Mitochondrial DNA replication and disease: insights from DNA polymerase γ mutations
Stumpf, J. D., & Copeland, W. C. (2010) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-010-0530-4 · Cited by 126
The expanding spectrum of biological actions of vitamin D
Rojas-Rivera, J. E., de la Piedra, C., Ramos, A., Ortíz, A., & Egido, J. (2010) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfq313 · Cited by 126
Self-citationParsonage, M., Wilkins, E. G., Snowden, N., Issa, B. G., & Savage, M. (2005) · HIV Medicine · doi:10.1111/j.1468-1293.2005.00318.x · Cited by 115
Tenofovir-induced kidney disease: an acquired renal tubular mitochondriopathy
Perazella, M. A. (2010) · Kidney International · doi:10.1038/ki.2010.344 · Cited by 105
Mitochondrial Tubulopathy in Tenofovir Disoproxil Fumarate-Treated Rats
Lebrecht, D., Venhoff, A. C., Kirschner, J., Wiech, T., Venhoff, N., & Walker, U. A. (2009) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3181a666eb · Cited by 102
Gatanaga, H., Tachikawa, N., Kikuchi, Y., Teruya, K., Genka, I., Honda, M., Tanuma, J., Yazaki, H., Ueda, A., Kimura, S., et al. (2006) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2006.22.744 · Cited by 98
Côté, H. C. F., Magil, A. B., Harris, M., Scarth, B. J., Gadawski, I., Wang, N., Yu, E., Yip, B., Zalunardo, N., Werb, R., et al. (2006) · Antiviral Therapy · doi:10.1177/135965350601100108 · Cited by 97
Fisher, E. J., Chaloner, K. M., Cohn, D. L., Grant, L. B., Alston, B., Brosgart, C. L., Schmetter, B., El-Sadr, W. M., & Sampson, J. H. (2001) · AIDS · doi:10.1097/00002030-200109070-00013 · Cited by 95
Winston, A., Amin, J., Mallon, P. W. G., Marriott, D., Carr, A. D., Cooper, D., & Emery, S. (2006) · HIV Medicine · doi:10.1111/j.1468-1293.2006.00349.x · Cited by 94
Progressive Renal Tubular Dysfunction Associated with Long-Term Use of Tenofovir DF
Kinai, E., & Hanabusa, H. (2009) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2008.0202 · Cited by 81
Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults
Ortíz, A., Oliveira, J. P., Wanner, C., Brenner, B. M., Waldek, S., & Warnock, D. G. (2008) · Nature Reviews Nephrology · doi:10.1038/ncpneph0806 · Cited by 80
Renal Disease in Patients with HIV Infection: Epidemiology, Pathogenesis and Management
Fine, D. M., Perazella, M. A., Lucas, G. M., & Atta, M. G. (2008) · Drugs · doi:10.2165/00003495-200868070-00006 · Cited by 79
Tenofovir renal safety in HIV-infected patients: Results from the SCOLTA Project
Madeddu, G., Bonfanti, P., Socio, G. V. D., Carradori, S., Grosso, C., Marconi, P., Penco, G., Rosella, E., Miccolis, S., Melzi, S., et al. (2007) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2007.04.008 · Cited by 72
Mechanisms of HIV and Nucleoside Reverse Transcriptase Inhibitor Injury to Mitochondria
Moyle, G. J. (2005) · Antiviral Therapy · doi:10.1177/135965350501002s05 · Cited by 71
Rosiglitazone: a European regulatory perspective
BLIND, E., Dunder, K., de Graeff, P. A., & Abadie, E. (2010) · Diabetologia · doi:10.1007/s00125-010-1992-5 · Cited by 70
Castillo, A. B., Tarantal, A. F., Watnik, M., & Martin, R. B. (2002) · Journal of Orthopaedic Research® · doi:10.1016/s0736-0266(02)00074-8 · Cited by 68
Perrot, S., Aslangul, E., Szwebel, T. A., Caillat‐Vigneron, N., & Jeunne, C. L. (2009) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0b013e31819c20d8 · Cited by 64
Rosiglitazone reverses tenofovir-induced nephrotoxicity
Libório, A. B., Andrade, L., Pereira, L. V. B., Sanches, T. R., Shimizu, M. H. M., & Seguro, A. C. (2008) · Kidney International · doi:10.1038/ki.2008.252 · Cited by 60
Cihlář, T., Laflamme, G., Fisher, R. L., et al. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01183-08 · Cited by 55
Rule, A. D. (2007) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e328057de8b · Cited by 54
Lanier, E. R., Ptak, R. G., Lampert, B. M., Keilholz, L., Hartman, T. L., Buckheit, R. W., Mankowski, M. K., Osterling, M. C., Almond, M. R., & Painter, G. R. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00068-10 · Cited by 46
Kim, M. J., Jardel, C., Barthélémy, C., Jan, V., Bastard, J. P., Filaut, S., Houry, S., Capeau, J., & Lombès, A. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01449-07 · Cited by 40
Irizarry-Alvarado, J. M., Dwyer, J. P., Brumble, L. M., Álvarez, S., & Mendez, J. (2009) · PubMed · Cited by 39
Young, B., Buchacz, K. A., Moorman, A. C., Wood, K. C., & Brooks, J. T. (2009) · AIDS Patient Care and STDs · doi:10.1089/apc.2008.0232 · Cited by 32
Izzedine, H., Thibault, V., Valantin, M., Peytavin, G., Schneider, L., & Benhamou, Y. (2010) · AIDS · doi:10.1097/qad.0b013e3283313f54 · Cited by 30
Metadata
- Authors
- Fernandez-Fernandez, B., Montoya-Ferrer, A., Sanz, A. B., Sanchez-Niño, M. D., Izquierdo, M. C., Poveda, J., Sainz-Prestel, V., Ortiz-Martin, N., Parra-Rodriguez, A., Selgas, R., Ruiz-Ortega, M., Egido, J., & Ortiz, A.
- Venue
- AIDS Research and Treatment
- Publisher
- Hindawi Limited
- Published
- 2011
- Volume
- 2011
- Pages
- 1-11
- ISSN
- 2090-1240 (ISSN-L)
- 2090-1259
- OpenAlex
- W2030888755
- Cited by
- 296
- References
- 64
- FWCI
- 13.81
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.